Developmental hip dysplasia or developmental dysplasia of the hip (DDH) includes a wide range of deformities of the hip, such as congenital dysplasia, subluxation, and dislocation. It is usually identified through neonatal screening during the first 6–8 weeks of life. The incidence of DDH ranges from 1–7% in neonates among some populations, but this may vary among different ethnicities and countries. A consensus about the ideal age for screening has not been reached to date. The aim of this study is to summarize the existing data regarding the incidence of congenital hip dysplasia and screening tests among European countries. The authors conducted a systematic search in PubMed/Medline and Scopus and collected original studies published in English, French or German. The incidence of DDH presents fluctuations, not only among European countries, but also within the same country. There is no unanimity regarding the screening methods of DDH; in some countries, universal ultrasound is proposed as the basic screening method for neonates for DDH; in other countries screening is performed only in high-risk cases. More robust data are needed to conclude which screening approach is associated with improved long-term outcomes.

Pyoderma gangrenosum is a severe and rare neutrophilic disorder that can present as a complication following any kind of surgery, usually after breast and abdominal surgery. This condition mimics infection, delaying prompt diagnosis and appropriate treatment with high dose of corticosteroids. We describe a case of pyoderma gangrenosum after hip hemiarthroplasty, in an 86-year-old woman, who sustained a neck of femur fracture after a simple fall. The patient was diagnosed 2 weeks postoperatively with pyoderma gangrenosum through a biopsy with clinical manifestations from other systems such as seizures and atrial fibrillation.

Background: Slipped capital femoral epiphysis (SCFE) is an adolescent hip disorder of high clinical importance in which diagnostic delay may lead to irreversible complications and long-term morbidity, and its incidence varies considerably across populations. Objective: The primary aim of this study was to provide contemporary, population-based incidence estimates of SCFE among children aged 6–16 years in Crete (2021–2024), addressing the lack of data from Greece and Southern Europe. A secondary aim was to contextualize these findings through a focused synthesis of international incidence reports published since 2015. Methods: All pediatric orthopedic specialists in Crete reported incident SCFE cases, all of which were radiographically confirmed. All confirmed cases of SCFE were documented. Annual population data for children aged 6–16 years were obtained from the Hellenic Statistical Authority. Incidence rates were expressed per 100,000 children aged 6–16 (95% CI, exact Poisson). A structured literature search (2015–May 2025) identified recent studies reporting SCFE incidence. Results: Eleven children with SCFE were identified (14 affected hips; three bilateral cases), corresponding to an incidence of 4.6 per 100,000 person-years (95% CI 2.5–7.8) among children aged 6–16 years. Mean age at presentation was 10.72 years, 64% were female, and 82% were obese, with comorbidity findings recorded. The literature review (2015–May 2025; 14 studies) demonstrated substantial geographic variation in SCFE incidence, ranging from ~5 per 100,000 in Mediterranean settings to 57 per 100,000 boys aged 9–15 years in Sweden. The Cretan incidence rate was broadly consistent with other Mediterranean reports. Conclusions: SCFE is an uncommon condition in Crete, with incidence rates comparable to those of other Mediterranean populations. The geographically defined setting and relatively stable demographics support case ascertainment and the interpretability of the incidence estimates. Larger nationwide studies are warranted to better characterize SCFE epidemiology in Greece.